Table 1. Summary of conventionally fractionated 2D or 3D-CRT reirradiation studies.
| Study | No. patients | Histology | Staging | Median interval to reRT (mo) | Initial RT dose Gy (median) | ReRT dose Gy (median) | Local control | Median OS mo (range) | Other therapies | Toxicities |
|---|---|---|---|---|---|---|---|---|---|---|
| Green & Melbye [1982] | 29 | NSCLC (94%), SCLC (6%) | Not described | 10 | 53 | 35 | Not described | 5 [1–54] | 24% of patients received chemotherapy after initial RT | <10% with “none-serious” complications |
| Jackson & Ball [1987] | 22 | NSCLC (86%), other (14%) | Not described | 15 | 55 | 30 | Not described | 5.4 (NS) | Not described | One patient with spinal cord injury, no other serious complications |
| Montebellow et al. [1993] | 30 | NSCLC (80%), other (20%) | I: 6/30; II: 1/30; III: 23/30 | 12 | 60 | 30 | Not described | 5 (NS) | 27% of patients received chemotherapy after initial RT | Esophagitis (20%), symptomatic pneumonitis (3.3%) |
| Gressen et al. [2000] | 23 | NSCLC (73%), other (27%) | Not described | 15 | 59 | 30 | Not described | 4.9 (NS) | 17% of patients received chemotherapy after initial RT | ≥ acute grade 3 toxicity in one patient |
| Okamoto et al. [2002] | 34 | NSCLC (68%), other (32%) | I–II: 2/34; III: 19/34; IV: 13/34 | 23 | 60 | 50 | Not described | 8 [1–58] | Not described | Symptomatic pneumonitis (56%), esophagitis (17.6%) |
| Wu et al. [2003] | 23 | NSCLC (70%), SCLC (30%) | II: 7/23; III: 16/23 | 13 | 66 | 51 | 51% locoregional PFS at 1 year | 14 [2–37] | Chemotherapy with reRT was optional; median of one cycle given (range, 1–3) sequentially | Grade 1–2 esophagitis (9%), grade 1–2 pneumonitis (22%), grade 2–3 pulmonary fibrosis (26%) |
| Tada et al. [2005] | 19 | NSCLC (95%), other (5%) | All stage III | 17 | 50–70 | 50 | Not described | 7 (0–56) | Not described | Grade 3 pneumonitis (5.3%), grade 2 esophagitis (15.8%) |
| Ebara et al. [2007] | 44 | NSCLC (69%), SCLC (20%), other (11%) | Not described | 12.6 | 60 | 40 | Not described | 6.5 [1–50] | Not described | Grade 2–3 toxicities (13.6%) |
| Ohguri et al. [2012] | 33 | NSCLC | I: 2/33; II: 4/33; III: 17/33; IV: 4/33; post-op: 6/33 | 7.9 | 70 | 50 | Median LC of 12.1 months | 18.1 (NS) | All patients received concurrent hyperthermia with reRT; 46% of patients received hyperthermia with initial RT; 46% of patients received concurrent CRT with reRT | Acute grade 3 toxicities seen in 9% of patients; no grade 4 or 5 toxicities; three patients experiences thermal burns |
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; NS, not stated; EBRT, external beam radiation therapy; IMRT, intensity modulated radiation therapy; PBT, proton beam therapy; SBRT, stereotactic body radiation therapy; RT, radiation therapy; reRT, reirradiation therapy; PFS, progression-free survival; LC, local control.